Gapping up
In reaction to strong earnings/guidance:
- JCP +20.2%, JD +13.3%, CRC +12.7%, RUBI +10.8%, COLL +9.3%, CVNA +8.8%, ENDP +8.3%, TWNK +8.2%, TPC +7.2%, MNST +6.9%, RGNX +6.1%, SOI +5.9%, ECA +5.8%, BILI +5.7%, FGEN +5.7%, BUD +5.6%, HGV +5%, KW +5%, JCAP +4.8%, NRG +4.8%, FTAI +4.6%, WTI +4.2%, CARS +3.6%, STAY +3.3%, NLSN +3.2%, FG +3.1%, ANSS +3.1%, GKOS +3%, ERI +2.9%, FOLD +2.7%, IRDM +2.6%, DAR +2.5%, UHS +2.5%, XLRN +2.4%, DAVA +2.4%, APA +1.4%, CWEN +1.4%, TTI +1.4%, FRO +1.3%, VET +1.2%, ATSG +1%
Other news:
- TTOO +24.5% (granted Breakthrough Device designation for the T2Resistance Panel by FDA)
- HZNP +23.1% (announces top-line results from Phase 3 confirmatory trial evaluating teprotumumab met primary endpoint)
- SRRA +15.4% (announces late-breaking oral and poster presentations for SRA737 and SRA141 preclinical data at AACR 2019)
- WBC +8.1% (WABCO Holdings confirms it has been approached by ZF Friedrichshafen AG and has engaged in preliminary discussions concerning a potential transaction)
- GH +7.1% (announces positive results from NILE study)
- TBIO +6.4% (provides update on cystic fibrosis and ornithine transcarbamylase deficiency programs; FDA to require additional preclinical toxicology data for MRT5201)
- ECA +5.8% (receives regulatory approvals for its planned $1.25 bln share buyback)
- IMGN +5.4% (modestly rebounding)
- KPTI +2.7% (Point72 Asset Management increases passive stake)
- BMY +1.9% (Bristol-Myers Squibb 8% shareholder Wellington Management says does not support proposed acquisition of Celgene)
Analyst comments:
- HAIN +6.4% (upgraded to Overweight from Neutral at JP Morgan)
- ENPH +2.8% (target raised to $12 at H.C. Wainwright)
- GMED +1.7% (upgraded to Buy from Neutral at UBS)
- VSTO +0.9% (initiated with a Buy at B. Riley